Gene silencing of the p15/INK4B cell-cycle inhibitor by hypermethylation: An early or later epigenetic alteration in myelodysplastic syndromes?

Leukemia

Volumn 17, Issue 9, 2003, Pages 1762-1764

  Lubbert M ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; DNA; DNA METHYLTRANSFERASE; MESSENGER RNA; PROTEIN P15; PROTEIN P16;

ACUTE GRANULOCYTIC LEUKEMIA; BONE MARROW CANCER; CANCER RISK; CANCER SURVIVAL; CELL ADHESION; CELL DIFFERENTIATION; CELL PROLIFERATION; CLINICAL TRIAL; DETOXIFICATION; DNA REPAIR; DOSE RESPONSE; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; MEGAKARYOCYTE; METASTASIS; MOLECULAR MECHANICS; MYELODYSPLASTIC SYNDROME; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTEIN FUNCTION; PROTEIN METHYLATION; PROTEIN TARGETING; SHORT SURVEY; SIGNAL TRANSDUCTION; SOUTHERN BLOTTING;

EID: 0142261186     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2403045     Document Type: Short Survey

References (33)

1. INK4B gene methylation in myelodysplastic syndromes. Leukemia 2003 (in press).
2. Mizuno S, Chijiwa T, Okamura T, Akashi K, Fukumaki Y, Niho Y et al. Expression of DNA methyltransferases DNMT1, 3A, and 3B in normal hematopoiesis and in acute and chronic myelogenous leukemia. Blood 2001; 97: 1172-1179.
3. Esteller M. CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future. Oncogene 2002; 21: 5427-5440.
4. Santini V, Kantarjian HM, Issa JP. Changes in DNA methylation in neoplasia: pathophysiology and therapeutic implications. Ann Intern Med 2001; 134: 573-586.
5. Chim CS, Liang R, Kwong YL. Hypermethylation of gene promoters in hematological neoplasia. Hematol Onco 2002; 20: 167-176.
6. Malumbres M, Perez de Castro I, Santos J, Melendez B, Mangues R, Serrano M et al. Inactivation of the cyclin-dependent kinase inhibitor p15INK4b by deletion and de novo methylation with independence of p16INK4a alterations in murine primary T-cell lymphomas. Oncogene 1997; 14: 1361-1370.
7. Latres E, Malumbres M, Sotillo R, Martin J, Ortega S, Martin-Caballero J et al. Limited overlapping roles of P15(INK4b) and P18(INK4c) cell cycle inhibitors in proliferation and tumorigenesis. EMBO J 2000; 19: 3496-3506.
8. Teofili L, Rutella S, Chiusolo P, La Barbera EO, Rumi C, Ranelletti FO et al. Expression of p15INK4B in normal hematopoiesis. Exp Hematol 1998; 26: 1133-1139.
9. Teofili L, Morosetti R, Martini M, Urbano R, Putzulu R, Rutella S et al. Expression of cyclin-dependent kinase inhibitor p15(INK4B) during normal and leukemic myeloid differentiation. Exp Hematol 2000; 28: 519-526.
10. Sakashita K, Koike K, Kinoshita T, Shiohara M, Kamijo T, Taniguchi S et al. Dynamic DNA methylation change in the CpG island region of p15 during human myeloid development. J Clin Invest 2001; 108: 1195-1204.
11. Teofili L, Martini M, Di Mario A, Rutella S, Urbano R, Luongo M et al. Expression of p15(ink4b) gene during megakaryocytic differentiation of normal and myelodysplastic hematopoietic progenitors. Blood 2001; 98: 495-497.
12. Wong IH, Ng MH, Huang DP, Lee JC. Aberrant p15 promoter methylation in adult and childhood acute leukemias of nearly all morphologic subtypes: potential prognostic implications. Blood 2000; 95: 1942-1949.
13. Chim CS, Liang R, Tam CY, Kwong YL. Methylation of p15 and p16 genes in acute promyelocytic leukemia: potential diagnostic and prognostic significance. J Clin Oncol 2001; 19: 2033-2040.
14. Herman JG, Civin CI, Issa JP, Collector MI, Sharkis SJ, Baylin SB. Distinct patterns of inactivation of p15INK4B and p16INK4A characterize the major types of hematological malignancies. Cancer Res 1997; 57: 837-841.
15. ink4b gene in myelodysplastic syndromes. Blood 1997; 90: 1403-1409.
16. INK4b gene in myelodysplastic syndromes is frequent and acquired during disease progression. Blood 1998; 91: 2985-2990.
17. Hofmann WK, Koeffler HP. Important features of myelodysplastic syndrome. Int J Hematol 2002; 76 (Suppl 2): 222-227.
18. INK4B gene in hematopoietic progenitors and peripheral blood cells in myelodysplastic syndromes. Leukemia 2000; 14: 586-593.
19. INK4B gene in myelodysplastic syndrome: it can be detected early at diagnosis or during disease progression and is highly associated with leukaemic transformation. Br J Haematol 2001; 112: 148-154.
20. Preisler HD, Li B, Chen H, Fisher L, Nayini J, Raza A et al. p15INK4B gene methylation and expression in normal, myelodysplastic, and acute myelogenous leukemia cells and in the marrow cells of cured lymphoma patients. Leukemia 2001; 15:: 1589-1595.
21. Daskalakis M, Ngyuyen TT, Nguyen C, Guldberg P, Köhler G, Wijermans P et al. Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-aza-2′deoxycytidine (decitabine) treatment. Blood 2002; 100: 2957-2963.
22. Chen H, Wu S. Hypermethylation of the p15(INK4B) gene in acute leukemia and myelodysplastic syndromes. Chin Med J 2002; 115: 987-990.
23. Au WY, Fung A, Man C, Ma SK, Wan TS, Liang R et al. Aberrant p15 gene promoter methylation in therapy-related myelodysplastic syndrome and acute myeloid leukaemia: clincopathological and karyotypic associations. Br J Haematol 2003; 120: 1062-1065.
24. Nguyen C, Liang G, Ngyuen TT, Tsao-Wie D, Groshen S, Lübbert M et al. Susceptibility of nonpromoter CpG islands to de novo methylation in normal and neoplastic cells. J Natl Canc Inst 2001; 93: 1465-1472.
25. Robertson KD, Uzvolgyi E, Liang G, Talmadge C, Sumegi J, Gonzales FA et al. The human DNA methyltransferases (DNMTs)1, 3a and 3b: coordinate mRNA expression in normal tissues and overexpression in tumors. Nucleic Acids Res 1999; 27: 2291-2298.
26. INK4a and RASSF1A in human lung cancer cell lines. Oncogene 2002; 21: 4822-4829.
27. Eads CA, Danenberg KD, Kawakami K, Saltz LB, Danenberg PV, Laird P. CpG island hypermethylation in human colorectal tumors is not associated with DNA methyltransferase overexpression. Cancer Res 1999; 59: 2302-2306.
28. Rhee I, Bachmann KE, Park BH, Jair KW, Yen RW, Schuebel KE et al. DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature 2002; 416: 552-556.
29. Ehrlich M, Jiang G, Fiala F, Dome JS, Yu MC, Long TI et al. Hypomethylation and hypermethylation of DNA in Wilm's tumors. Oncogene 2002; 21: 6694-6702.
30. Nguyen CT, Gonzales FA, Jones PA. Altered chromatin structure associated with methylation-induced gene silencing in cancer cells: correlation of accessibility, methylation, MeCP2 binding and acetylation. Nucleic Acids Res 2001; 29: 4598-4606.
31. Wijermans PW, Lübbert M, Verhoef G, Bosly A, Ravoet C, Andre M et al. Low-dose 5-Aza-2′-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome; a multicenter phase II study in elderly patients. J Clin Oncol 2000; 18: 956-962.
32. Silverman LR, Demakos EP, Peterson BL, Kornblith AB, Holland JC, Odchimar-Reissig R et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 2002; 20: 2429-2440.
33. Bender CM, Pao MM, Jones PA. Inhibition of DNA methylation by 5-Aza-2′-deoxycytidine suppresses the growth of human tumor cell lines. Cancer Res 1998; 58: 95-101.